Tumorigenic effects were also likely mediated by activation of the JAK2/JAK3 kinase signalling pathway, and blocking the SLC6A14/JAK2/JAK3 axis has therefore been proposed as a potential therapeutic strategy for CRC [14]. The gene discussed is JAK3; the disease is colorectal carcinoma.